Abstract

ROSANOVA, María T et al. Use of posaconazole in children: Experience in a tertiary pediatric hospital. Arch. argent. pediatr. [online]. 2018, vol.116, n.3, pp.e451-e454. ISSN 0325-0075.  http://dx.doi.org/10.5546/aap.2018.e451.

There is limited information on the use of posaconazole in children. This retrospective and descriptive study was conducted to evaluate the clinical, microbiological characteristics and evolution of patients treated with posaconazole between August 2010 and March 2017. We included 16 children. Median age: 161 months (interquartile range -IQR-69-173m). All had underlying disease and a proven invasive fungal infection. The most frequent isolated were Mucor spp. and Aspergillus spp. The mean posaconazole dose was 600 mg /day (400-800 mg/day) and the median duration of treatment was 223 days (IQR 48-632). Ten patients had adverse effects, but only one required suspension of the antifungal treatment due to hydroelectrolytic disorders.

Keywords : Posaconazole; Treatment; Invasivefungal infections; Child.